Fluticasone + vilanterol

ArticlesNew Medicines ·
23662511000001107

Articles

New Medicines

Relvar Ellipta (EU), Revinty Ellipta (EU), Breo Ellipta (US) Regular treatment of asthma in children aged 6 years and older not adequately controlled with inhaled corticosteroids and as needed inhaled short acting beta-2-agonists

Information

Relvar Ellipta (EU), Revinty Ellipta (EU), Breo Ellipta (US)
Licence extension / variation
GlaxoSmithKline
GlaxoSmithKline

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Long-acting beta agonist (LABA) in combination with the once-a-day inhaled corticosteroid (ICS), fluticasone furoate (FF)
5.4 million people in the UK receive treatment for asthma: 1 in 11 children and 1 in 12 adults. It is the most common chronic medical condition in children [1].
Regular treatment of asthma in children aged 6 years and older not adequately controlled with inhaled corticosteroids and as needed inhaled short acting beta-2-agonists
Inhalation